|Bid||0.1150 x N/A|
|Ask||0.1200 x N/A|
|Day's Range||0.1150 - 0.1200|
|52 Week Range||0.1100 - 0.1800|
|Beta (3Y Monthly)||-0.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 31, 2019 - May 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MedX Health Corp. (“MedX”) (MDX.V) announces it will initiate a targeted marketing campaign following an announcement by a worldwide coalition of researchers and clinicians who have agreed that light therapy is among the most effective interventions for the prevention of oral mucositis and painful ulcers in the mouth and throat resulting from cancer therapy. The Company said this represents a significant sales opportunity in Canada and the United States for MedX’s photobiomodulation therapy devices.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has signed a non-exclusive, performance-based distribution agreement with Group Vida, to distribute MedX’s DermSecureTM skin cancer assessment technology platform in the USA, Canada and Israel. MedX has previously signed an exclusive distribution agreement for Brazil with CBD Vida LTDA, a Partner of Group Vida. The process for regulatory approval in Brazil is proceeding extremely well according to Peter Abboud, Group Vida’s CEO.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has partnered with SANITAS, a specialist in healthcare and well-being services in Spain, to conduct a skin cancer screening initiative. According to recent studies, Spain, with its warm and sunny climate has experienced a 50% increase in skin cancer rates over the last decade. It is the most common form of cancer in women between the age of 25 and 29, followed by breast cancer, and the most common in men between the age of 30 and 35, ahead of lung and colon cancer.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the three-months ended March 31, 2019, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $184,801 for the three months ended March 31, 2019, compared with revenue of $226,122 for the three months ended March 31, 2018. Revenues from SIAscopy of $21,563 were lower than the 2018 three-month period, and revenue from the Company's therapeutic laser line of $163,238 were 13% lower than in the prior year.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the year ended December 31, 2018, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $1,087,426 for the year ended December 31, 2018, compared with revenue of $1,093,239 for the year ended December 31, 2017. Sales from the Company's SIAscopy skin assessment technology increased by 26.5% during 2018, while the sales from the therapeutic laser line were down by 8.7%.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) is pleased to announce that it has obtained Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 15,625,000 units at $0.16 per unit (“Unit”), to raise up to $2,500.000. Each Unit will be comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.25, exercisable for a period of two years from the date of issue. Qualified Agents may receive commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) equal in number to 6% of the number of units so subscribed for.
MedX Health Corp. (“MedX”) (MDX.V) announced today that it has signed an Exclusive Distribution Agreement with CBD Vida (“Vida”), to launch a comprehensive, ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM Telemedicine platform. This exclusive distribution agreement is a natural progression of the earlier Memorandum of Understanding with Vida “because their reach in the Brazilian marketplace is robust and extensive,” said Scott Spearn, President & CEO of MedX. There are almost 212 million Brazilian people, where skin cancer is the most common form of cancer,” said Camata Candello, Vida’s CEO.
MedX Health Corp. announces that it has signed an agreement with Richmar, a Compass Health Brands Company, to manufacture and supply selected Private Label Laser and Light products to Richmar for the US rehabilitation market.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has signed a Memorandum of Understanding with CBD Vida LTDA, who plans to launch an ease-of-access skin scanning/assessment program throughout Brazil, using MedX’s DermSecureTM. "There is a significant opportunity for MedX’s skin imaging technology in Brazil, as skin cancer is the most common type of cancer in Brazil,” stated Fabio Camata Candello, CBD Vida LTDA’s CEO. More than one hundred thousand new cases of skin cancer were recorded in Brazil between 2016 and 2017, according to the Brazilian Cancer Institute, and almost 6,000 were classified as melanoma, an aggressive form of the disease that can spread to other parts of the body.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 2,962,500 Units on January 28, 2019, to raise $474,000 from accredited investors pursuant to a Private Placement Offering originally announced on November 23, 2018. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange. MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology.
MedX Health Corp. (“MedX”) (MDX.V) announced today that Dr. Bruno Battistini, a Canadian-based health care researcher and medical business advisor has joined MedX’s Medical Advisory Board. “While the members of our Medical Advisory Board to date are esteemed physicians and researchers specializing in skin cancer and other Dermatological conditions, Dr. Battistini complements the group by providing a breadth of experience dealing with policy, and bridging the gap with government, health care agencies and providers to gain access to Canadian markets,” said Scott Spearn, CEO of MedX.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announced its results for the three and nine months ended September 30, 2018, which are also available on SEDAR (www.sedar.com). MedX launched the Company’s ground-breaking DermSecureTM telemedicine platform during the third quarter. “DermSecureTM makes MedX’s rapid skin cancer assessment solution commercially scalable on a global basis,” commented Scott Spearn, CEO of MedX.
MedX Health Corp. (“MedX”) (MDX.V) announces that it has signed a Memorandum of Understanding with a consortium of Dutch companies that will be launching an easy-access skin scanning/assessment program in the Netherlands, using MedX’s SIAscopy and DermSecureTM technologies. The consortium will integrate DermSecureTM with their existing platforms, which includes a suite of software applications used by a large majority of general practitioners in the Netherlands, and will build awareness campaigns through established healthcare initiatives and programs. “The Dutch team is impressed with SIAscopy’s unique scanning technology, and the ability to seamlessly integrate our DermSecureTM platform into their suite of medical software applications that are used by more than 4,500 physicians in the Netherlands makes it a natural fit,” noted Scott Spearn, MedX’s President and CEO.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an additional Closing of 1,137,500 Units on November 22, 2018, to raise $182,000 from accredited investors pursuant to a Private Placement Offering originally announced on October 11, 2018. Following this Closing, MedX has 135,053,901 common shares issued and outstanding. The Company also announces that it is initiating a new, non-brokered, Private Placement offering of Units to raise up to $2.5 million from accredited investors.
MedX Health Corp. (“MedX”) (MDX.V) announces that it is initiating the development of an Artificial Intelligence Engine with leading dermatologists and its technology partner, Blanc Labs, that will work in conjunction with its existing DermSecureTM screening platform. MedX has an opportunity to leverage Artificial Intelligence to create a unique assessment support tool allowing Dermatologists to more accurately assess suspicious moles and lesions from remote locations. MedX’s advanced SIAscopy imaging technology lends itself to AI because of the specialized image capture above and below the skin’s surface.
MedX Health Corp. (“MedX”) (MDX.V) announced today that Dr. Eggert Stockfleth, Director of the University Department of Dermatology at St. Josef-Hospital in Bochum, Germany has agreed to join MedX’s Medical Advisory Board. Dr. Stockfleth was previously the Director of the Skin Cancer Center in Berlin. “The addition of Dr. Stockfleth to our Medical Advisory Board completes our group of highly accomplished physicians from around the world.
MedX Health Corp. (“MedX” or the “Company”) (MDX.V) announces the following changes to its Board and Executive team, effective immediately. Scott Spearn, who joined the Company as President in April 2018 is taking on the additional role of Chief Executive Officer and is joining the Board of Directors. Rob von der Porten, previously the CEO, has been appointed as Chairman of the Board in place of Gary Van Nest who has retired from that position and remains as a director.
MedX Health Corp. (“MedX”) (MDX.V) announced today that it is launching DermSecure™, its telemedicine platform, in six Ontario clinics. MedX will begin rolling out DermSecure™ across Ontario and subsequently Canada while finalizing its introduction into a number of international markets. MedX’s DermSecure™ has been built to the leading data repository standards to allow for integration with Electronic Medical Record (EMR’s) systems.